Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice.
Chronic administration of triazolam (0.25 mg/kg/day, i.p.) on days 1-8 and its withdrawal produced an anxiogenic reaction in mice as assessed in the mirrored-chamber test. Daily administration of bupropion (2 or 5 mg/kg, i.p.) prior to triazolam for 8 days prevented withdrawal-induced anxiety in mice. Triazolam withdrawal also induced a significant increase in the locomotor activity of mice indicating an anxiogenic response. Daily administration of bupropion (2 or 5 mg/kg) prior to triazolam for 8 days also prevented withdrawal-induced increased locomotor activity. In conclusion, chronic administration of bupropion (2 and 5 mg/kg) exhibited a significant protection against triazolam withdrawal-induced anxiety and hyperlocomotor activity in mice. The result suggests the protective effect of bupropion in the management of triazolam withdrawal reactions.
Joshi
Dipesh
D
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Naidu
Pattipati S
PS
Singh
Amanpreet
A
Kulkarni
Shrinivas K
SK
D000818:Animals; D001007:Anxiety / Q000188:drug therapy*; D016642:Bupropion / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004361:Drug Tolerance; D005260:Female; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D009638:Norepinephrine / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000523:psychology; D014229:Triazolam / Q000494:pharmacology*
D016642:Bupropion; D014229:Triazolam; D004298:Dopamine; D009638:Norepinephrine